Proteogenomic integration reveals therapeutic targets in breast cancer xenografts

Citations Over TimeTop 1% of 2017 papers

Abstract

Abstract Recent advances in mass spectrometry (MS) have enabled extensive analysis of cancer proteomes. Here, we employed quantitative proteomics to profile protein expression across 24 breast cancer patient-derived xenograft (PDX) models. Integrated proteogenomic analysis shows positive correlation between expression measurements from transcriptomic and proteomic analyses; further, gene expression-based intrinsic subtypes are largely re-capitulated using non-stromal protein markers. Proteogenomic analysis also validates a number of predicted genomic targets in multiple receptor tyrosine kinases. However, several protein/phosphoprotein events such as overexpression of AKT proteins and ARAF, BRAF, HSP90AB1 phosphosites are not readily explainable by genomic analysis, suggesting that druggable translational and/or post-translational regulatory events may be uniquely diagnosed by MS. Drug treatment experiments targeting HER2 and components of the PI3K pathway supported proteogenomic response predictions in seven xenograft models. Our study demonstrates that MS-based proteomics can identify therapeutic targets and highlights the potential of PDX drug response evaluation to annotate MS-based pathway activities.

Related Papers

• → Proteogenomics: From next-generation sequencing (NGS) and mass spectrometry-based proteomics to precision medicine(2019)59 cited
• → SpectroGene: A Tool for Proteogenomic Annotations Using Top-Down Spectra(2015)14 cited
• → Network motifs modulate druggability of cellular targets(2016)13 cited
• → Whole proteome analysis of post-translational modifications: Applications of mass-spectrometry for proteogenomic annotation(2007)192 cited
• Advances in computational mass spectrometry: Phosphoproteomics and proteogenomics(2008)